澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

IMMUTEP LTD

0.027

+0.0013.85%

成交量：1,585.61万

成交额：41.87万

市值：3,979.05万

市盈率：-0.50

高：0.028

开：0.027

低：0.025

收：0.026

52周最高：0.470

52周最低：0.025

股本：14.74亿

流通股本：12.28亿

量比：1.69

换手率：1.29%

股息：- -

股息率：- -

每股收益(TTM):-0.054

每股收益(LYR):-0.054

净资产收益率：-77.31%

总资产收益率：-42.45%

市净率：0.65

市盈率(LYR):-0.50

数据加载中...

总览公司新闻资讯公告

Immutep公布一线非小细胞肺癌临床进展：INSIGHT-003研究成熟总生存期数据积极，TACTI-004研究同步更新

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IMM.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.027,"timestamp":1791781920000,"preClose":0.026,"halted":0,"volume":15856060,"delay":0,"changeRate":0.0384615384615385,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"未开盘","change":0.001,"latestTime":"10-12 16:12:00 AEDT","open":0.027,"high":0.028,"low":0.025,"amount":418731,"amplitude":0.115385,"askPrice":0.028,"askSize":1501704,"bidPrice":0.027,"bidSize":199315,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.026,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":1.6934415827739442,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.026,"auctionPrice":0.027,"auctionVolume":765801,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781805232}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":1.6934415827739442,"shares":1473721306,"dividePrice":0,"high":0.028,"amplitude":0.115385,"preClose":0.026,"low":0.025,"week52Low":0.025,"pbRate":"0.65","psRate":"2.00","week52High":0.47,"institutionHeld":0,"latestPrice":0.027,"committee":-0.765652,"eps":-0.0539,"divideRate":0,"volume":15856060,"delay":0,"ttmEps":-0.0539,"open":0.027,"prevYearClose":0.415,"prevWeekClose":0.026,"prevMonthClose":0.034,"prevQuarterClose":0.034,"fiveDayClose":0.031,"twentyDayClose":0.047,"sixtyDayClose":0.05,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142240576","title":"Immutep公布一线非小细胞肺癌临床进展：INSIGHT-003研究成熟总生存期数据积极，TACTI-004研究同步更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1142240576","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142240576?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944153,"startTime":"0","endTime":"0","summary":"Immutep公司近日发布了一线非小细胞肺癌治疗领域的重要临床更新。其中，INSIGHT-003研究的成熟总生存期数据呈现出积极信号，同时，TACTI-004研究也提供了最新进展。INSIGHT-003研究旨在评估Immutep核心候选药物与标准疗法联合用于一线治疗的效果。这项研究评估了另一种联合治疗方案在特定非小细胞肺癌患者群体中的疗效与安全性。这两项研究的积极进展，标志着Immutep在肿瘤免疫治疗领域，特别是一线非小细胞肺癌这一巨大未满足需求的适应症上，取得了阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}